Navigation Links
Breast Cancer Drugs May Fight Cervical Cancer, Too
Date:11/9/2009

Study in mice reports success with drugs that inhibit estrogen,,

MONDAY, Nov. 9 (HealthDay News) -- Two drugs used to treat breast cancer and osteoporosis eliminated cervical cancer in mice, according to a new study.

The drugs also cleared precancerous growths in the cervix and vagina, and prevented the onset of cancer in mice with precancerous lesions.

The breast cancer drug fulvestrant and the breast cancer/osteoporosis drug raloxifene were given to mice genetically engineered to carry human papillomavirus (HPV) 16, which is strongly associated with cervical cancer. Both drugs prevent estrogen from working in cells. Fulvestrant is marketed for women as Faslodex, and raloxifene is marketed as Evista.

The study appears in this week's issue of the Proceedings of the National Academy of Sciences.

"We have begun to test whether the drugs are as effective in treating cervical cancer in human cells as they are in our mice," senior study author Dr. Paul F. Lambert, an oncology professor at the University of Wisconsin School of Medicine and Public Health, said in a university news release.

If the lab studies, expected to take one or two years, are successful, they could be followed quickly by clinical trials, the researchers said.

Nearly all cervical cancers test positive for HPV 16, Lambert said, but not all women infected with HPV get cervical cancer, which has led researchers to examine other factors.

"Since the cervix and other female reproductive organs are so responsive to estrogen, our lab and others began to focus on that hormone," he explained.

Fulvestrant and raloxifene block a receptor (estrogen receptor alpha) that mediates estrogen function in cells.

"We can't be sure how the science will translate from animals to humans, but we have faith in our mouse model," Lambert said. "There are many similarities in how cervical cancer develops and manifests itself in women and in mice."

More information

The U.S. National Women's Health Information Center has more about cervical cancer.



-- Robert Preidt



SOURCE: University of Wisconsin, news release, Nov. 9, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... , ... Offering the purest product of its kind, Swissx Labs AG has ... than the market has seen before. Swissx uses proprietary strains of hemp plants grown ... process for extraction, to produce its CBD oil--maximizing its benefits for health and wellness. ...
(Date:4/26/2017)... ... 2017 , ... Journal of Oral Implantology – Tooth loss is ... dental health, including complications with speech, eating, and overcompensation of mouth due to the ... teeth. As the number of tooth replacements increase, it is imperative to design an ...
(Date:4/26/2017)... ... April 26, 2017 , ... The National Business Research ... National Registry of Emergency Medical Technicians and welcomes this organization to the ... Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. “This award ...
(Date:4/26/2017)... ... April 26, 2017 , ... New SUPRO® ... ready-to-drink, high-protein beverages by helping beverage manufacturers more effectively manage protein costs. “Soy ... cost savings as well as more stable pricing over time. Now it’s even ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... an agreement to be the preferred physical therapy provider for Derby City CrossFit, ... to Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports physical ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology: